Industry Supported Sessions

​Hall A

Tuesday, 6 May 2014

13.00 - 14.30

ASTRA ZENECA

VACCINATING CHILDREN AGAINST INFLUENZA – UPDATE ON RECENT CHANGES IN EUROPE

15.00 - 16.30

GSK

PUBLIC HEALTH STRATEGIES TO PREVENT BACTERIAL DISEASES IN CHILDHOOD

Wednesday, 7 May 2014

08.45 - 10.15

               SANOFI PASTEUR MSD

IMPROVING IMPLEMENTATION OF VACCINATION PROGRAMS

10.45 - 12.15

ABBVIE

THE ONGOING GLOBAL CHALLENGE OF RSV INFECTION: EMERGING INTERVENTIONS AGAINST RSV

13.00 - 14.30

GSK

CERVARIX® 2-DOSE SCHEDULE*: A NEW CHAPTER IN CERVICAL CANCER PREVENTION

 PROSPECTS OF A REDUCED SCHEDULE IN HPV VACCINATION

15.00 - 16.30

NOVARTIS VACCINES

TRANSFORMING THE LANDSCAPE OF MENINGOCOCCAL DISEASE PREVENTION

16.50 - 18.20

PFIZER

PNEUMOCOCCAL VACCINATION: WHERE WE ARE AND WHERE WE ARE GOING

​​​TUESDAY, MAY 6, 2014

VACCINATING CHILDREN AGAINST INFLUENZA – UPDATE ON RECENT CHANGES IN EUROPE

13:00 - 14:30

Chairperson: R. Belshe, USA

13:00–13:10        WELCOME AND INTRODUCTION
                           
R. Belshe, USA, Chair

13:10–13:30        PAEDIATRIC INFLUENZA IMMUNISATION POLICY – THE NORDIC PERSPECTIVE 
                            T. Kilpi, Finland

13:30–13:50        EFFECTIVENESS DATA AND POLICY UPDATE FROM GERMANY
                           
M. Rose, Germany

13:50–14:15        THE 2013/14 UK (SCOTLAND) CHILDHOOD VACCINATION PROGRAMME – HOW
                             DID IT GO?
                            
J. McMenamin, UK

14:15–14:30        QUESTIONS AND PANEL 
                             Discussion led by R. Belshe, Chair

*************************************************************************

PUBLIC HEALTH STRATEGIES TO PREVENT BACTERIAL DISEASES IN CHILDHOOD 

15:00-16:30

15:00 – 15:10 WELCOME AND INTRODUCTION
                       
M. Slack, UK

15:10 – 15:30 STRATEGIES TO HELP PROTECT AGAINST MENINGOCOCCAL DISEASES
                     
 V. Papaevangelou, Greece

15:30 – 15:50 LESSONS LEARNT FROM PNEUMOCOCCAL VACCINATION PROGRAMMES
                      
A. Palmu, Finland

15:50 – 16:10 PERTUSSIS: WHY DO WE NEED A LIFE-LONG STRATEGY?
                     
 C. Wirsing von Koenig, Germany

16:10 – 16:20 CONCLUDING REMARKS
                      
M.Slack, UK

16:20 – 16:30 Q&A

WEDNESDAY, MAY 7, 2014

 IMPROVING IMPLEMENTATION OF VACCINATION PROGRAMS

8:45 - 10:15

Chair: Prof. Ulrich Heininger

ROUTINE PAEDIATRIC VACCINATION IN EUROPE. SUCCESS AND CHALLENGES
U. Heininger

A NEW HEXAVALENT VACCINE UP TO CURRENT TIMES' EXPECTATIONS
F. Martinon-Torres

INTRODUCTION OF MMR/V VACCINES IN EU CHILDHOOD VACCINATION PROGRAMS
C. Giaquinto

HPV VACCINATION IN PRE-TEENS AND TEENS: INFORMATION, CHECK-UP AND CATCH-UP
C. Weil-Olivier

*************************************************************************

THE ONGOING GLOBAL CHALLENGE OF RSV INFECTION: EMERGING INTERVENTIONS AGAINST RSV

10:45– 12:15

10:45-10:50   WELCOME AND INTRODUCTION     
                      Eleanor Molloy
10:50-11:15   NOVEL INSIGHTS IN RSV PATHOGENESIS, PREVENTION AND TREATMENT
                      Louis Bont
11:15-11:40   THE DEVELOPMENT OF THE PRETERM NEONATAL IMMUNE SYSTEM AND NEW
                      EVIDENCE ON THE ROLE OF VITAMIN D​

                      Eleanor Molloy 
11:40-12:05   ADVANCES IN RSV VACCINE DEVELOPMENT
                      Barnie Graham
12:05-12:15   Q&A

*************************************************************************

CERVARIX® 2-DOSE SCHEDULE*: A NEW CHAPTER IN CERVICAL CANCER PREVENTION

PROSPECTS OF A REDUCED SCHEDULE IN HPV VACCINATION

13.00 - 14.30​

Moderator:
Mark Porter UK

Participants:
M. Van Ranst Belgium
C. Dannecker Germany
T. Schwarz Germany
C. Weil-Olivier, France

13:00–13:05 HPV AND CERVICAL CANCER – VIDEO

13:05–13:10 WELCOME AND INTRODUCTION

13:10–14:15 SHORT PRESENTATIONS AND ROUNDTABLE DISCUSSION ON FOLLOWING
                     
TOPICS:

          • Incidence of cervical cancer
          • Prevention of cervical cancer through screening and vaccination
          • HPV vaccination compliance and coverage
          • Cervical cancer and its treatments
          • Introduction of Cervarix® 2-dose vaccination schedule* and results of clinical trials
          • Immunise today to protect later: the role of paediatricians in vaccination of young adolescent girls

14:15–14:25 Q&A

14:25–14:30 CONCLUSIONS

* Cervarix® 2-dose vaccination schedule is registered for 9-14 years old girls

*************************************************************************

TRANSFORMING THE LANDSCAPE OF MENINGOCOCCAL DISEASE PREVENTION

15:00–16:30

15:00–15:10  WELCOME AND OPENING
                     
A Nicholson, Programme Co-Chair

15:10–15:25  EPIDEMIOLOGY OF MENINGOCOCCAL DISEASE: ASSESSING AN UNPREDICTABLE
                      BURDEN
                      
S. Black

15:25–15:40  THE POTENTIAL LONG-TERM IMPLICATIONS OF SURVIVING MENINGOCOCCAL
                       DISEASE
                      
S. Nadel

15:40–16:00  BREAKING BARRIERS IN THE FIGHT AGAINST MENINGOCOCCAL SEROGROUP B
                      DISEASE
                     
F. Martinón-Torres

16:00–16:20  UNDERSTANDING PARENTAL ACCEPTANCE OF NEW VACCINES
                     
W. Fisher

16:20–16:30  Q&A AND CLOSING REMARKS
                     
R. Rappuoli, Programme Co-Chair

*************************************************************************

 For information, visit our booth​.

PNEUMOCOCCAL VACCINATION: WHERE WE ARE AND WHERE WE ARE GOING

16:50-18:20

Chair: K. Connolly, Ireland
Co-chair: H.Schmitt, France

16:50   WELCOME AND INTRODUCTION
            K. Connolly, Ireland
            H.Schmitt, France

17:00   THE BENEFITS OF PCV13 - WHERE WE ARE TODAY 
             R. Sâ-Leâo, Portugal

17:20   CLINICAL PRACTICE IN THE ERA OF PNEUMOCOCCAL CONJUGATE VACCINATION
             I. De Schutter, Belgium

17:40   VACCINES FOR THE FUTURE – WHAT ARE THE CHALLENGES?
            U. Heininger, Switzerland 

18:00   Q&A AND CLOSURE
            K. Connolly, Ireland
            H. Schmitt, France

Keep Me Updated

key dates

Key Dates